Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Short-Term Debt repayments (2020 - 2025)

Ani Pharmaceuticals' Short-Term Debt repayments history spans 6 years, with the latest figure at -$6.1 million for Q4 2025.

  • For Q4 2025, Short-Term Debt repayments fell 102.09% year-over-year to -$6.1 million; the TTM value through Sep 2025 reached $297.1 million, up 39712.4%, while the annual FY2024 figure was $292.5 million, N/A changed from the prior year.
  • Short-Term Debt repayments for Q4 2025 was -$6.1 million at Ani Pharmaceuticals, down from $2.0 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $291.0 million in Q4 2024 and bottomed at -$6.1 million in Q4 2025.
  • The 5-year median for Short-Term Debt repayments is $1.4 million (2022), against an average of $30.6 million.
  • The largest annual shift saw Short-Term Debt repayments surged 13033.33% in 2024 before it crashed 102.09% in 2025.
  • A 5-year view of Short-Term Debt repayments shows it stood at $192.1 million in 2021, then crashed by 101.17% to -$2.2 million in 2022, then changed by 0.0% to -$2.2 million in 2023, then soared by 13033.33% to $291.0 million in 2024, then plummeted by 102.09% to -$6.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Short-Term Debt repayments are -$6.1 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025).